137 related articles for article (PubMed ID: 3285909)
1. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.
Lyons J; Janssen JW; Bartram C; Layton M; Mufti GJ
Blood; 1988 Jun; 71(6):1707-12. PubMed ID: 3285909
[TBL] [Abstract][Full Text] [Related]
2. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
[TBL] [Abstract][Full Text] [Related]
3. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome.
de Souza Fernandez T; Menezes de Souza J; Macedo Silva ML; Tabak D; Abdelhay E
Leuk Res; 1998 Feb; 22(2):125-34. PubMed ID: 9593469
[TBL] [Abstract][Full Text] [Related]
4. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.
Janssen JW; Buschle M; Layton M; Drexler HG; Lyons J; van den Berghe H; Heimpel H; Kubanek B; Kleihauer E; Mufti GJ
Blood; 1989 Jan; 73(1):248-54. PubMed ID: 2562924
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.
Neubauer A; Greenberg P; Negrin R; Ginzton N; Liu E
Leukemia; 1994 Apr; 8(4):638-41. PubMed ID: 7512175
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
[TBL] [Abstract][Full Text] [Related]
7. Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value.
Constantinidou M; Chalevelakis G; Economopoulos T; Koffa M; Liloglou T; Anastassiou C; Yalouris A; Spandidos DA; Raptis S
Ann Hematol; 1997 Jan; 74(1):11-4. PubMed ID: 9031609
[TBL] [Abstract][Full Text] [Related]
8. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.
Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F
Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.
Lorenzo F; Nishii K; Monma F; Kuwagata S; Usui E; Shiku H
Leuk Res; 2006 Oct; 30(10):1235-9. PubMed ID: 16533529
[TBL] [Abstract][Full Text] [Related]
10. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
[TBL] [Abstract][Full Text] [Related]
12. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.
Padua RA; Carter G; Hughes D; Gow J; Farr C; Oscier D; McCormick F; Jacobs A
Leukemia; 1988 Aug; 2(8):503-10. PubMed ID: 3166076
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
[TBL] [Abstract][Full Text] [Related]
14. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Janssen JW; Steenvoorden AC; Lyons J; Anger B; Böhlke JU; Bos JL; Seliger H; Bartram CR
Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9228-32. PubMed ID: 3122217
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
16. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
19. Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease.
Melani C; Haliassos A; Chomel JC; Miglino M; Ferraris AM; Gaetani GF; Kaplan JC; Kitzis A
Br J Haematol; 1990 Apr; 74(4):408-13. PubMed ID: 2189488
[TBL] [Abstract][Full Text] [Related]
20. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
Venkatraj VS; Gaidano G; Auerbach AD
Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
